Post Market Clinical Follow-up of CODMAN CERTAS Programmable Valve

Inclusion Criteria:

1. Patient and/or legally authorized representative has agreed to participate in thestudy by signing the EC-approved consent form, where applicable.

2. Patients (of any age) who underwent or who plan to have a surgical procedureutilizing one of the Codman CERTAS Plus Programmable Valves.

3. Patient (legally designated representative) is willing to comply with the studyprotocol timelines & requirements.

4. For patients who have had the Codman CERTAS Plus Programmable Valve implanted priorto study enrollment, have available data from implantation to the current time.

Exclusion Criteria:

1. Patients undergoing implantation of the CODMAN CERTAS Plus Programmable Valve as arevision procedure.

2. Patient's planned shunt has distal drainage to the heart.

3. Patient has ventriculitis, peritonitis or meningitis.

4. Patient has sepsis.

5. Patient has a history of poor wound healing.

6. Patient has symptoms pertaining to a skin infection at or near the site of anyincisions; an ear infection on either side; a respiratory tract infection; or aurinary tract infection that, in the Investigator's opinion is clinicallysignificant and might compromise the outcome of this study.

7. Patient has had any form of bowel surgery 30 days prior to device implant oranticipates bowel surgery within 90 days following device implant.

8. Patient is otherwise determined by the Investigator to be medically unsuitable forparticipation in this study.

9. Patient is currently enrolled in another drug or device trial or has been previouslyentered in this trial.

10. Patient is a prisoner or member of a different vulnerable population that should notbe included in the study per the investigator.

11. Patients with known hypersensitivity to rifampin or clindamycin hydrochloride. Thiscriterion applies for patients to be treated with the BACTISEAL Catheters (includedin some models of the valve) only.